Viatris Innovation GmbH — Biomedical Watch V2

Traitements11programmes

Essais6liés

Publications4liées

SourceDBlocale

Traitements

11

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
CenerimodThe goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are: * Does cenerimod improve kidney function in participants? * What medical problems do participants have when taking cenerimod? Researchers will compare cenerimod to a placebo (a look-alike substance that contains no drug) to see how well cenerimod works when it is added to regular treatment. Participants will: * Take cenerimod or a placebo every day for 76 weeks (approximately 1.5 years), on top of regular treatment. * Visit the clinic every 1 to 3 months for checkups and tests.	Lupus	Phase 3	À vérifier	United States, Argentina, Brazil, Bulgaria, Chile, Colombia, Czechia, France, …	À vérifier
Cenerimod 0.5 mgThe purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).	Lupus	Phase 2	À vérifier	United States, Bulgaria, Chile, Czechia, France, Georgia, Germany, Greece, …	À vérifier
Cenerimod 1 mgThe purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).	Lupus	Phase 2	À vérifier	United States, Bulgaria, Chile, Czechia, France, Georgia, Germany, Greece, …	À vérifier
Cenerimod 2 mgThe purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).	Lupus	Phase 2	À vérifier	United States, Bulgaria, Chile, Czechia, France, Georgia, Germany, Greece, …	À vérifier
cenerimod 2 mg (ex-4 mg)The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).	Lupus	Phase 2	À vérifier	United States, Bulgaria, Chile, Czechia, France, Georgia, Germany, Greece, …	À vérifier
CenerimodThe goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are: * Does cenerimod improve kidney function in participants? * What medical problems do participants have when taking cenerimod? Researchers will compare cenerimod to a placebo (a look-alike substance that contains no drug) to see how well cenerimod works when it is added to regular treatment. Participants will: * Take cenerimod or a placebo every day for 76 weeks (approximately 1.5 years), on top of regular treatment. * Visit the clinic every 1 to 3 months for checkups and tests.	Lupus	Phase 3	À vérifier	United States	À vérifier
Cenerimod 0.5 mgThe purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).	Lupus	Phase 2	À vérifier	United States, Bulgaria, Chile, Czechia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Mexico, Philippines, Poland, Puerto Rico, Romania, Russia, Spain, Taiwan, …	À vérifier
CenerimodThe goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are: * Does cenerimod improve kidney function in participants? * What medical problems do participants have when taking cenerimod? Researchers will compare cenerimod to a placebo (a look-alike substance that contains no drug) to see how well cenerimod works when it is added to regular treatment. Participants will: * Take cenerimod or a placebo every day for 76 weeks (approximately 1.5 years), on top of regular treatment. * Visit the clinic every 1 to 3 months for checkups and tests.	Lupus	Phase 1/2	À vérifier	United States, Belarus, Bulgaria, Georgia, Russia, Ukraine	À vérifier
CenerimodThe goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are: * Does cenerimod improve kidney function in participants? * What medical problems do participants have when taking cenerimod? Researchers will compare cenerimod to a placebo (a look-alike substance that contains no drug) to see how well cenerimod works when it is added to regular treatment. Participants will: * Take cenerimod or a placebo every day for 76 weeks (approximately 1.5 years), on top of regular treatment. * Visit the clinic every 1 to 3 months for checkups and tests.	Lupus	Phase 3	À vérifier	United States, Argentina, Brazil, Bulgaria, Colombia, France, Greece, India, Japan, Mexico, Philippines, Poland, Romania, South Korea, Taiwan, Thailand, Ukraine	À vérifier
CenerimodThe goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are: * Does cenerimod improve kidney function in participants? * What medical problems do participants have when taking cenerimod? Researchers will compare cenerimod to a placebo (a look-alike substance that contains no drug) to see how well cenerimod works when it is added to regular treatment. Participants will: * Take cenerimod or a placebo every day for 76 weeks (approximately 1.5 years), on top of regular treatment. * Visit the clinic every 1 to 3 months for checkups and tests.	Lupus	Phase 3	À vérifier	United States, Argentina, Brazil, Bulgaria, Chile, Colombia, Czechia, France, Georgia, Germany, Greece, Malaysia, Mexico, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Serbia, …	À vérifier
CenerimodThe goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are: * Does cenerimod improve kidney function in participants? * What medical problems do participants have when taking cenerimod? Researchers will compare cenerimod to a placebo (a look-alike substance that contains no drug) to see how well cenerimod works when it is added to regular treatment. Participants will: * Take cenerimod or a placebo every day for 76 weeks (approximately 1.5 years), on top of regular treatment. * Visit the clinic every 1 to 3 months for checkups and tests.	Lupus	Phase 3	À vérifier	United States, Chile, Czechia, Georgia, Germany, India, Malaysia, Mexico, Peru, Philippines, Poland, Portugal, Puerto Rico, Serbia, South Africa, Spain, Ukraine, United Kingdom	À vérifier

Essais cliniques

6

Molécule	Indication / population	Phase	NCT	Titre	Statut
Cenerimod	Lupus	Phase 3	NCT05672576	OPUS-2 — A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus	ACTIVE_NOT_RECRUITING
Cenerimod	Lupus	Phase 3	NCT06475742	OPUS OLE — Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus	ENROLLING_BY_INVITATION
Cenerimod	Lupus	Phase 3	NCT05648500	OPUS-1 — A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus	ACTIVE_NOT_RECRUITING
Cenerimod	Lupus	Phase 1/2	NCT02472795	Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus	COMPLETED
Cenerimod 0.5 mg	Lupus	Phase 2	NCT03742037	Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus	COMPLETED
Cenerimod	Lupus	Phase 3	NCT07201129	LUMIOS — A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment	RECRUITING

Publications

4

Molécule	Indication / population	Titre	Journal	Date
Cenerimod		The contribution of the sphingosine 1-phosphate signaling pathway to chronic kidney diseases: recent findings and new perspectives.	Pflugers Archiv : European journal of physiology
Cenerimod 1 mg		Evolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review.	Cureus
Cenerimod		Pharmacodynamics of the S1P receptor modulator cenerimod in a phase 2b randomised clinical trial in patients with moderate to severe SLE.	Annals of the rheumatic diseases
Cenerimod		Comparative effectiveness and safety of biologics and targeted small-molecule therapies plus stable background therapy in systemic lupus erythematosus: a systematic review and network meta-analysis.	Frontiers in immunology